SCHEMBL7680879

SCHEMBL7680879

Cn1c(C(=O)c2ccc(C#N)cc2)cc2c1CC(=O)O2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
PKM P14618 1/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
KMO O15229 1/20 0.34
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MMP1 P03956 1/20 0.33
HCRTR2 O43614 1/20 0.33
JAK2 O60674 1/20 0.33
TRPA1 O75762 1/20 0.33
GPR35 Q9HC97 1/20 0.33
GSK3B P49841 2/20 0.33
AURKA O14965 1/20 0.33
MAP4K4 O95819 1/20 0.33
CHEK2 O96017 1/20 0.33
PRKCG P05129 1/20 0.33
PHKG2 P15735 1/20 0.33
MARK3 P27448 1/20 0.33
FLT3 P36888 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7675598 0.85 CXCL8 (0.41) ALDH1A1MAPTSMN1; SMN2
SCHEMBL7676913 0.84 HTT (0.46) ALDH1A1PKMCA2MAPTSMN1; SMN2
SCHEMBL7681406 0.84 NPC1 (0.39) ALDH1A1MAPTSMN1; SMN2CASP1CASP7
SCHEMBL7674503 0.84 KMT2A (0.37) ALDH1A1MAPTSMN1; SMN2CYP3A4
SCHEMBL7676981 0.84 CA12 (0.34) ALDH1A1PKMCA1CA2MAPT
SCHEMBL7678452 0.81 RAB9A (0.39) ALDH1A1MAPTSMN1; SMN2CYP3A4CNR1
SCHEMBL7683734 0.81 HPGD (0.44) ALDH1A1MAPTALOX15
SCHEMBL7678332 0.81 SRD5A2 (0.39) ALDH1A1MAPTSMN1; SMN2
SCHEMBL7683451 0.79 CA12 (0.33) ALDH1A1MAPTDYRK1AALOX15
SCHEMBL7678438 0.77 HPGD (0.42) ALDH1A1MAPTCNR2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885PKM 4613/4885CA1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.